Global Radiopharmaceutical CDMO/CMO Services Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 7.0 Billion by the year 2034 at a 9.2% CAGR during the forecast period for 2025-2034.
Radiopharmaceutical drugs, introduced with radioactive isotopes, are pivotal in both diagnosing and treating medical conditions. These compounds emit detectable radiation, helping in the visualization of specific organs or tissues through techniques like scintigraphy. Radiopharmaceutical CDMO/CMO services offer specialized outsourcing solutions for the development and manufacturing of these drugs, ensuring regulatory compliance and expertise from drug initiation to commercialization.
These services are integral in optimizing the manufacturing process and providing regulatory guidance, enabling pharmaceutical companies to focus on core objectives like drug development. With a growing emphasis on early-stage clinical support, the integration of CRO and CMO capabilities into a unified CDMO model has become prevalent. Selecting the right CDMO or CMO is crucial for comprehensive support throughout the drug development and manufacturing journey, including early-phase research and beyond.
The rise in chronic diseases like cancer and cardiovascular disorders is fueling the demand for radiopharmaceuticals, essential for diagnostic imaging and therapy. This demand pushes pharmaceutical companies to outsource complex manufacturing to CDMOs to cut costs, accelerate product launches, and meet growing needs effectively. Additionally, research advancements and the trend toward personalized medicine are driving the exponential growth of the Radiopharmaceutical CDMO market.
The radiopharmaceutical CDMO/CMO services market is segmented based on application, type of radioisotope, scale of operation, source of manufacturing and therapeutic area. By application the market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, Diagnostic radiopharmaceutical segment is categorized into positron emission tomography radiopharmaceuticals and SPECT Radiopharmaceuticals, Therapeutic radiopharmaceutical segment is sub-segmented into alpha emitters, beta emitters and other therapeutic radiopharmaceuticals, By type of radioisotope, market is segmented into technetium-99m, fluorine-18, leutetium-177, gallium-68, actinium-225 and other radioisotopes. Based on source of manufacturing, market is divided into nuclear reactors and cyclotrons, On the basis of scale of operation, market is segmented into preclinical, clinical and commercial. By therapeutic area, market is categorized into cardiovascular disorders, neurological disorders, oncological disorders and other disorders.
The diagnostic radiopharmaceutical segment is expected to dominate the market. This segment has shown dominance in the market, with a significant contribution to market growth. Diagnostic radiopharmaceuticals play a crucial role in nuclear medicine by enabling the visualization and diagnosis of various medical conditions through imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The diagnostic radiopharmaceuticals segment is essential for providing accurate and detailed imaging for medical professionals to diagnose and monitor diseases effectively, making it a key driver in the Radiopharmaceutical CDMO/CMO Services Market. According to World Nuclear Association, over 10,000 hospitals globally use radioisotopes for a range of therapeutic and diagnostic applications.
The oncology segment in the radiopharmaceutical CDMO/CMO services market is growing rapidly due to several factors. These include the increasing incidence of cancer, advancements in radiopharmaceutical technology, and supportive regulatory approvals. Strategic collaborations and investments, the trend towards personalized medicine, and the aging population further drive demand. Additionally, increased funding for cancer research and improved production capabilities by CDMOs/CMOs contribute to this growth. Overall, the need for innovative cancer diagnostics and treatments is propelling the expansion of the oncology segment.
North America dominates half of the world's radiopharmaceutical production, showing that many pharmaceutical companies and services are based there. The region's rising demand for radiopharmaceuticals, driven by the growing number of chronic diseases like cancer and heart problems, is pushing companies to outsource the making of these drugs to CDMOs and CMOs, fueling the growth of this market.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.9 Billion |
|
Revenue Forecast In 2034 |
USD 7.0 Billion |
|
Growth Rate CAGR |
CAGR of 9.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, By Type of Radioisotope, By Source of Manufacturing, By Therapeutic Area and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; Germany, Denmark, Turkey, Romania, Bulgaria, Austria, Norway, China; Australia; Taiwan; Thailand; South Korea; Rest of Asia Pacific; Brazil; Rest of Latin America; France; Kuwait; U.A.E.; Egypt; Rest of MEA |
|
Competitive Landscape |
Minerva Imaging, Evergreen Theragnostics, Inc., NMR (NorthStar Medical Radioisotopes), PharmaLogic, Eckert & Ziegler, AtomVie, Eczac?ba??-Monrol, Cardinal Health, Nucleus RadioPharma, Seibersdorf Labor GmbH, Global Medical Solutions, SOFIE, SpectronRx, Agilera Pharma AS, Grupo RPH, and Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceutical CDMO/CMO Services Market Snapshot
Chapter 4. Global Radiopharmaceutical CDMO/CMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
Chapter 5. Market Segmentation 1: By Manufacturing Source Estimates & Trend Analysis
5.1. By Manufacturing Source & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Manufacturing Source:
5.2.1. Nuclear Reactors
5.2.2. Cyclotrons
Chapter 6. Market Segmentation 2: By Manufacturing Source Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Diagnostic Radiopharmaceuticals
6.2.1.1. Positron Emission Tomography Radiopharmaceuticals
6.2.1.2. SPECT Radiopharmaceuticals
6.2.2. Therapeutic Radiopharmaceuticals
6.2.2.1. Alpha Emitters
6.2.2.2. Beta Emitters
6.2.2.3. Other Therapeutic Radiopharmaceuticals
Chapter 7. Market Segmentation 3: By Operation Scale Estimates & Trend Analysis
7.1. By Operation Scale & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Operation Scale:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Market Segmentation 4: By Radioisotope Estimates & Trend Analysis
8.1. By Radioisotope & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Radioisotope:
8.2.1. Technetium-99m
8.2.2. Fluorine-18
8.2.3. Leutetium-177
8.2.4. Gallium-68
8.2.5. Actinium-225
8.2.6. Other Radioisotopes
Chapter 9. Market Segmentation 5: By Therapeutic Area Estimates & Trend Analysis
9.1. By Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
9.2.1. Cardiovascular Disorders
9.2.2. Neurological Disorders
9.2.3. Oncology
9.2.4. Other Therapeutic Area
Chapter 10. Radiopharmaceutical CDMO/CMO Services Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.1.2. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.1.3. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.1.4. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.1.5. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.1.6. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.1.6.1. U.S.
10.1.6.2. Canada
10.2. Europe
10.2.1. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.2.2. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.2.3. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.2.4. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.2.5. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.2.6. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.2.6.1. Germany
10.2.6.2. Denmark
10.2.6.3. Turkey
10.2.6.4. Romania
10.2.6.5. Bulgaria
10.2.6.6. Austria
10.2.6.7. Norway
10.2.6.8. Rest of Europe
10.3. Asia Pacific
10.3.1. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.3.2. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.3.3. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.3.4. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.3.5. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.3.6. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.3.6.1. China
10.3.6.2. Australia
10.3.6.3. Taiwan
10.3.6.4. South Korea
10.3.6.5. Thailand
10.3.6.6. Rest of Asia Pacific
10.4. Latin America
10.4.1. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.4.2. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.4.3. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.4.4. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.4.5. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.4.6. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.4.6.1. Brazil
10.4.6.2. Rest of Latin America
10.5. Middle East & Africa
10.5.1. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.5.2. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.5.3. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.5.4. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.5.5. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.5.6. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.5.6.1. Kuwait
10.5.6.2. U.A.E.
10.5.6.3. Egypt
10.5.6.4. Rest of MEA
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Minerva Imaging
11.2.2. Evergreen Theragnostics, Inc.
11.2.3. NMR (NorthStar Medical Radioisotopes)
11.2.4. PharmaLogic
11.2.5. Eckert & Ziegler
11.2.6. AtomVie
11.2.7. Eczac?ba??-Monrol
11.2.8. Cardinal Health
11.2.9. Nucleus RadioPharma
11.2.10. Seibersdorf Labor GmbH
11.2.11. Global Medical Solutions
11.2.12. SOFIE
11.2.13. SpectronRx
11.2.14. Agilera Pharma AS
11.2.15. Siemens Healthineers
11.2.16. Almac Group
11.2.17. Medi-Radiopharma
11.2.18. Itm Radiopharma
11.2.19. Nihon Medi-Physics Co., Ltd.
11.2.20. IONETIX Corporation
11.2.21. GBI
11.2.22. DuchemBio, Co., Ltd.
11.2.23. Grupo RPH
11.2.24. Other Prominent Players
Radiopharmaceutical CDMO/CMO Services Market -By Application
Radiopharmaceutical CDMO/CMO Services Market -By Type of Radioisotope
Radiopharmaceutical CDMO/CMO Services Market -By Source of Manufacturing
Radiopharmaceutical CDMO/CMO Services Market -By Scale of Operation
Radiopharmaceutical CDMO/CMO Services Market -By Therapeutic Area
Radiopharmaceutical CDMO/CMO Services Market -By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
